 | • レポートコード：MRC2-11QY12292 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、132ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はIBS治療のグローバル市場について調査・分析したレポートです。種類別（IBS-D、IBS-C、IBS-M）市場規模、用途別（病院、クリニック、研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別IBS治療の競争状況、市場シェア ・世界のIBS治療市場：種類別市場規模 2015年-2020年（IBS-D、IBS-C、IBS-M） ・世界のIBS治療市場：種類別市場規模予測 2021年-2026年（IBS-D、IBS-C、IBS-M） ・世界のIBS治療市場：用途別市場規模 2015年-2020年（病院、クリニック、研究所） ・世界のIBS治療市場：用途別市場規模予測 2021年-2026年（病院、クリニック、研究所） ・北米のIBS治療市場分析：米国、カナダ ・ヨーロッパのIBS治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのIBS治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のIBS治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのIBS治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Allergan Plc (Ireland)、Sucampo Pharmaceuticals (U.S.)、Ironwood Pharmaceuticals, Inc. (U.S.)、Astellas Pharma Inc. (Japan)、Bausch Health、Abbott Laboratories (U.S.)、Synergy Pharmaceuticals, Inc. (U.S.)、Ardelyx, Inc. (U.S.)、Nestle (Switzerland)、Sebela Pharmaceuticals (Ireland)、Probi (Sweden)、Alfasigma USA, Inc. (Italy)、RedHill Biopharma Ltd. (Israel)、AstraZeneca (U.K)、Ipsen (France)、Novartis AG (Switzerland)、Takeda Pharmaceutical Company Ltd (Japan)、Synthetic Biologics, Inc. (U.S.)、Protagonist Therapeutics Inc. (U.S.)、Pfizer Inc (U.S.)、Lexicon Pharmaceuticals, Inc. (U.S.)、Innovate Biopharmaceuticals (U.S.) ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
Market Analysis and Insights: Global IBS Treatment Market
The global IBS Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global IBS Treatment Scope and Market Size
IBS Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global IBS Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Allergan Plc (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals, Inc. (U.S.)
Astellas Pharma Inc. (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals, Inc. (U.S.)
Ardelyx, Inc. (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA, Inc. (Italy)
RedHill Biopharma Ltd. (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Ltd (Japan)
Synthetic Biologics, Inc. (U.S.)
Protagonist Therapeutics Inc. (U.S.)
Pfizer Inc (U.S.)
Lexicon Pharmaceuticals, Inc. (U.S.)
Innovate Biopharmaceuticals (U.S.)
Market segment by Type, the product can be split into
IBS-D
IBS-C
IBS-M
Market segment by Application, split into
Hospitals
Clinics
Research Laboratories
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by IBS Treatment Revenue
1.4 Market by Type
1.4.1 Global IBS Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 IBS-D
1.4.3 IBS-C
1.4.4 IBS-M
1.5 Market by Application
1.5.1 Global IBS Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Research Laboratories
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global IBS Treatment Market Perspective (2015-2026)
2.2 Global IBS Treatment Growth Trends by Regions
2.2.1 IBS Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 IBS Treatment Historic Market Share by Regions (2015-2020)
2.2.3 IBS Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 IBS Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key IBS Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top IBS Treatment Players by Market Size
3.1.1 Global Top IBS Treatment Players by Revenue (2015-2020)
3.1.2 Global IBS Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global IBS Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global IBS Treatment Market Concentration Ratio
3.2.1 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by IBS Treatment Revenue in 2019
3.3 IBS Treatment Key Players Head office and Area Served
3.4 Key Players IBS Treatment Product Solution and Service
3.5 Date of Enter into IBS Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global IBS Treatment Historic Market Size by Type (2015-2020)
4.2 Global IBS Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global IBS Treatment Market Size by Application (2015-2020)
5.2 Global IBS Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America IBS Treatment Market Size (2015-2020)
6.2 IBS Treatment Key Players in North America (2019-2020)
6.3 North America IBS Treatment Market Size by Type (2015-2020)
6.4 North America IBS Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe IBS Treatment Market Size (2015-2020)
7.2 IBS Treatment Key Players in Europe (2019-2020)
7.3 Europe IBS Treatment Market Size by Type (2015-2020)
7.4 Europe IBS Treatment Market Size by Application (2015-2020)
8 China
8.1 China IBS Treatment Market Size (2015-2020)
8.2 IBS Treatment Key Players in China (2019-2020)
8.3 China IBS Treatment Market Size by Type (2015-2020)
8.4 China IBS Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan IBS Treatment Market Size (2015-2020)
9.2 IBS Treatment Key Players in Japan (2019-2020)
9.3 Japan IBS Treatment Market Size by Type (2015-2020)
9.4 Japan IBS Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia IBS Treatment Market Size (2015-2020)
10.2 IBS Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia IBS Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia IBS Treatment Market Size by Application (2015-2020)
11 India
11.1 India IBS Treatment Market Size (2015-2020)
11.2 IBS Treatment Key Players in India (2019-2020)
11.3 India IBS Treatment Market Size by Type (2015-2020)
11.4 India IBS Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America IBS Treatment Market Size (2015-2020)
12.2 IBS Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America IBS Treatment Market Size by Type (2015-2020)
12.4 Central & South America IBS Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Allergan Plc (Ireland)
13.1.1 Allergan Plc (Ireland) Company Details
13.1.2 Allergan Plc (Ireland) Business Overview
13.1.3 Allergan Plc (Ireland) IBS Treatment Introduction
13.1.4 Allergan Plc (Ireland) Revenue in IBS Treatment Business (2015-2020))
13.1.5 Allergan Plc (Ireland) Recent Development
13.2 Sucampo Pharmaceuticals (U.S.)
13.2.1 Sucampo Pharmaceuticals (U.S.) Company Details
13.2.2 Sucampo Pharmaceuticals (U.S.) Business Overview
13.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Introduction
13.2.4 Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2015-2020)
13.2.5 Sucampo Pharmaceuticals (U.S.) Recent Development
13.3 Ironwood Pharmaceuticals, Inc. (U.S.)
13.3.1 Ironwood Pharmaceuticals, Inc. (U.S.) Company Details
13.3.2 Ironwood Pharmaceuticals, Inc. (U.S.) Business Overview
13.3.3 Ironwood Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
13.3.4 Ironwood Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
13.3.5 Ironwood Pharmaceuticals, Inc. (U.S.) Recent Development
13.4 Astellas Pharma Inc. (Japan)
13.4.1 Astellas Pharma Inc. (Japan) Company Details
13.4.2 Astellas Pharma Inc. (Japan) Business Overview
13.4.3 Astellas Pharma Inc. (Japan) IBS Treatment Introduction
13.4.4 Astellas Pharma Inc. (Japan) Revenue in IBS Treatment Business (2015-2020)
13.4.5 Astellas Pharma Inc. (Japan) Recent Development
13.5 Bausch Health
13.5.1 Bausch Health Company Details
13.5.2 Bausch Health Business Overview
13.5.3 Bausch Health IBS Treatment Introduction
13.5.4 Bausch Health Revenue in IBS Treatment Business (2015-2020)
13.5.5 Bausch Health Recent Development
13.6 Abbott Laboratories (U.S.)
13.6.1 Abbott Laboratories (U.S.) Company Details
13.6.2 Abbott Laboratories (U.S.) Business Overview
13.6.3 Abbott Laboratories (U.S.) IBS Treatment Introduction
13.6.4 Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2015-2020)
13.6.5 Abbott Laboratories (U.S.) Recent Development
13.7 Synergy Pharmaceuticals, Inc. (U.S.)
13.7.1 Synergy Pharmaceuticals, Inc. (U.S.) Company Details
13.7.2 Synergy Pharmaceuticals, Inc. (U.S.) Business Overview
13.7.3 Synergy Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
13.7.4 Synergy Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
13.7.5 Synergy Pharmaceuticals, Inc. (U.S.) Recent Development
13.8 Ardelyx, Inc. (U.S.)
13.8.1 Ardelyx, Inc. (U.S.) Company Details
13.8.2 Ardelyx, Inc. (U.S.) Business Overview
13.8.3 Ardelyx, Inc. (U.S.) IBS Treatment Introduction
13.8.4 Ardelyx, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
13.8.5 Ardelyx, Inc. (U.S.) Recent Development
13.9 Nestle (Switzerland)
13.9.1 Nestle (Switzerland) Company Details
13.9.2 Nestle (Switzerland) Business Overview
13.9.3 Nestle (Switzerland) IBS Treatment Introduction
13.9.4 Nestle (Switzerland) Revenue in IBS Treatment Business (2015-2020)
13.9.5 Nestle (Switzerland) Recent Development
13.10 Sebela Pharmaceuticals (Ireland)
13.10.1 Sebela Pharmaceuticals (Ireland) Company Details
13.10.2 Sebela Pharmaceuticals (Ireland) Business Overview
13.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Introduction
13.10.4 Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2015-2020)
13.10.5 Sebela Pharmaceuticals (Ireland) Recent Development
13.11 Probi (Sweden)
10.11.1 Probi (Sweden) Company Details
10.11.2 Probi (Sweden) Business Overview
10.11.3 Probi (Sweden) IBS Treatment Introduction
10.11.4 Probi (Sweden) Revenue in IBS Treatment Business (2015-2020)
10.11.5 Probi (Sweden) Recent Development
13.12 Alfasigma USA, Inc. (Italy)
10.12.1 Alfasigma USA, Inc. (Italy) Company Details
10.12.2 Alfasigma USA, Inc. (Italy) Business Overview
10.12.3 Alfasigma USA, Inc. (Italy) IBS Treatment Introduction
10.12.4 Alfasigma USA, Inc. (Italy) Revenue in IBS Treatment Business (2015-2020)
10.12.5 Alfasigma USA, Inc. (Italy) Recent Development
13.13 RedHill Biopharma Ltd. (Israel)
10.13.1 RedHill Biopharma Ltd. (Israel) Company Details
10.13.2 RedHill Biopharma Ltd. (Israel) Business Overview
10.13.3 RedHill Biopharma Ltd. (Israel) IBS Treatment Introduction
10.13.4 RedHill Biopharma Ltd. (Israel) Revenue in IBS Treatment Business (2015-2020)
10.13.5 RedHill Biopharma Ltd. (Israel) Recent Development
13.14 AstraZeneca (U.K)
10.14.1 AstraZeneca (U.K) Company Details
10.14.2 AstraZeneca (U.K) Business Overview
10.14.3 AstraZeneca (U.K) IBS Treatment Introduction
10.14.4 AstraZeneca (U.K) Revenue in IBS Treatment Business (2015-2020)
10.14.5 AstraZeneca (U.K) Recent Development
13.15 Ipsen (France)
10.15.1 Ipsen (France) Company Details
10.15.2 Ipsen (France) Business Overview
10.15.3 Ipsen (France) IBS Treatment Introduction
10.15.4 Ipsen (France) Revenue in IBS Treatment Business (2015-2020)
10.15.5 Ipsen (France) Recent Development
13.16 Novartis AG (Switzerland)
10.16.1 Novartis AG (Switzerland) Company Details
10.16.2 Novartis AG (Switzerland) Business Overview
10.16.3 Novartis AG (Switzerland) IBS Treatment Introduction
10.16.4 Novartis AG (Switzerland) Revenue in IBS Treatment Business (2015-2020)
10.16.5 Novartis AG (Switzerland) Recent Development
13.17 Takeda Pharmaceutical Company Ltd (Japan)
10.17.1 Takeda Pharmaceutical Company Ltd (Japan) Company Details
10.17.2 Takeda Pharmaceutical Company Ltd (Japan) Business Overview
10.17.3 Takeda Pharmaceutical Company Ltd (Japan) IBS Treatment Introduction
10.17.4 Takeda Pharmaceutical Company Ltd (Japan) Revenue in IBS Treatment Business (2015-2020)
10.17.5 Takeda Pharmaceutical Company Ltd (Japan) Recent Development
13.18 Synthetic Biologics, Inc. (U.S.)
10.18.1 Synthetic Biologics, Inc. (U.S.) Company Details
10.18.2 Synthetic Biologics, Inc. (U.S.) Business Overview
10.18.3 Synthetic Biologics, Inc. (U.S.) IBS Treatment Introduction
10.18.4 Synthetic Biologics, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
10.18.5 Synthetic Biologics, Inc. (U.S.) Recent Development
13.19 Protagonist Therapeutics Inc. (U.S.)
10.19.1 Protagonist Therapeutics Inc. (U.S.) Company Details
10.19.2 Protagonist Therapeutics Inc. (U.S.) Business Overview
10.19.3 Protagonist Therapeutics Inc. (U.S.) IBS Treatment Introduction
10.19.4 Protagonist Therapeutics Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
10.19.5 Protagonist Therapeutics Inc. (U.S.) Recent Development
13.20 Pfizer Inc (U.S.)
10.20.1 Pfizer Inc (U.S.) Company Details
10.20.2 Pfizer Inc (U.S.) Business Overview
10.20.3 Pfizer Inc (U.S.) IBS Treatment Introduction
10.20.4 Pfizer Inc (U.S.) Revenue in IBS Treatment Business (2015-2020)
10.20.5 Pfizer Inc (U.S.) Recent Development
13.21 Lexicon Pharmaceuticals, Inc. (U.S.)
10.21.1 Lexicon Pharmaceuticals, Inc. (U.S.) Company Details
10.21.2 Lexicon Pharmaceuticals, Inc. (U.S.) Business Overview
10.21.3 Lexicon Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
10.21.4 Lexicon Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
10.21.5 Lexicon Pharmaceuticals, Inc. (U.S.) Recent Development
13.22 Innovate Biopharmaceuticals (U.S.)
10.22.1 Innovate Biopharmaceuticals (U.S.) Company Details
10.22.2 Innovate Biopharmaceuticals (U.S.) Business Overview
10.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Introduction
10.22.4 Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2015-2020)
10.22.5 Innovate Biopharmaceuticals (U.S.) Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. IBS Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by IBS Treatment Revenue
Table 3. Ranking of Global Top IBS Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global IBS Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of IBS-D
Table 6. Key Players of IBS-C
Table 7. Key Players of IBS-M
Table 8. Global IBS Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global IBS Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global IBS Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global IBS Treatment Market Share by Regions (2015-2020)
Table 12. Global IBS Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global IBS Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. IBS Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key IBS Treatment Players
Table 19. Global IBS Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global IBS Treatment Market Share by Players (2015-2020)
Table 21. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in IBS Treatment as of 2019)
Table 22. Global IBS Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players IBS Treatment Product Solution and Service
Table 25. Date of Enter into IBS Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global IBS Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global IBS Treatment Market Size Share by Type (2015-2020)
Table 29. Global IBS Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global IBS Treatment Market Size Share by Application (2015-2020)
Table 31. Global IBS Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global IBS Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players IBS Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players IBS Treatment Market Share (2019-2020)
Table 35. North America IBS Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America IBS Treatment Market Share by Type (2015-2020)
Table 37. North America IBS Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America IBS Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players IBS Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players IBS Treatment Market Share (2019-2020)
Table 41. Europe IBS Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe IBS Treatment Market Share by Type (2015-2020)
Table 43. Europe IBS Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe IBS Treatment Market Share by Application (2015-2020)
Table 45. China Key Players IBS Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players IBS Treatment Market Share (2019-2020)
Table 47. China IBS Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China IBS Treatment Market Share by Type (2015-2020)
Table 49. China IBS Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China IBS Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players IBS Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players IBS Treatment Market Share (2019-2020)
Table 53. Japan IBS Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan IBS Treatment Market Share by Type (2015-2020)
Table 55. Japan IBS Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan IBS Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players IBS Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players IBS Treatment Market Share (2019-2020)
Table 59. Southeast Asia IBS Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia IBS Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia IBS Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia IBS Treatment Market Share by Application (2015-2020)
Table 63. India Key Players IBS Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players IBS Treatment Market Share (2019-2020)
Table 65. India IBS Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India IBS Treatment Market Share by Type (2015-2020)
Table 67. India IBS Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India IBS Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players IBS Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players IBS Treatment Market Share (2019-2020)
Table 71. Central & South America IBS Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America IBS Treatment Market Share by Type (2015-2020)
Table 73. Central & South America IBS Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America IBS Treatment Market Share by Application (2015-2020)
Table 75. Allergan Plc (Ireland) Company Details
Table 76. Allergan Plc (Ireland) Business Overview
Table 77. Allergan Plc (Ireland) Product
Table 78. Allergan Plc (Ireland) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 79. Allergan Plc (Ireland) Recent Development
Table 80. Sucampo Pharmaceuticals (U.S.) Company Details
Table 81. Sucampo Pharmaceuticals (U.S.) Business Overview
Table 82. Sucampo Pharmaceuticals (U.S.) Product
Table 83. Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 84. Sucampo Pharmaceuticals (U.S.) Recent Development
Table 85. Ironwood Pharmaceuticals, Inc. (U.S.) Company Details
Table 86. Ironwood Pharmaceuticals, Inc. (U.S.) Business Overview
Table 87. Ironwood Pharmaceuticals, Inc. (U.S.) Product
Table 88. Ironwood Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 89. Ironwood Pharmaceuticals, Inc. (U.S.) Recent Development
Table 90. Astellas Pharma Inc. (Japan) Company Details
Table 91. Astellas Pharma Inc. (Japan) Business Overview
Table 92. Astellas Pharma Inc. (Japan) Product
Table 93. Astellas Pharma Inc. (Japan) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 94. Astellas Pharma Inc. (Japan) Recent Development
Table 95. Bausch Health Company Details
Table 96. Bausch Health Business Overview
Table 97. Bausch Health Product
Table 98. Bausch Health Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 99. Bausch Health Recent Development
Table 100. Abbott Laboratories (U.S.) Company Details
Table 101. Abbott Laboratories (U.S.) Business Overview
Table 102. Abbott Laboratories (U.S.) Product
Table 103. Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 104. Abbott Laboratories (U.S.) Recent Development
Table 105. Synergy Pharmaceuticals, Inc. (U.S.) Company Details
Table 106. Synergy Pharmaceuticals, Inc. (U.S.) Business Overview
Table 107. Synergy Pharmaceuticals, Inc. (U.S.) Product
Table 108. Synergy Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 109. Synergy Pharmaceuticals, Inc. (U.S.) Recent Development
Table 110. Ardelyx, Inc. (U.S.) Business Overview
Table 111. Ardelyx, Inc. (U.S.) Product
Table 112. Ardelyx, Inc. (U.S.) Company Details
Table 113. Ardelyx, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 114. Ardelyx, Inc. (U.S.) Recent Development
Table 115. Nestle (Switzerland) Company Details
Table 116. Nestle (Switzerland) Business Overview
Table 117. Nestle (Switzerland) Product
Table 118. Nestle (Switzerland) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 119. Nestle (Switzerland) Recent Development
Table 120. Sebela Pharmaceuticals (Ireland) Company Details
Table 121. Sebela Pharmaceuticals (Ireland) Business Overview
Table 122. Sebela Pharmaceuticals (Ireland) Product
Table 123. Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 124. Sebela Pharmaceuticals (Ireland) Recent Development
Table 125. Probi (Sweden) Company Details
Table 126. Probi (Sweden) Business Overview
Table 127. Probi (Sweden) Product
Table 128. Probi (Sweden) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 129. Probi (Sweden) Recent Development
Table 130. Alfasigma USA, Inc. (Italy) Company Details
Table 131. Alfasigma USA, Inc. (Italy) Business Overview
Table 132. Alfasigma USA, Inc. (Italy) Product
Table 133. Alfasigma USA, Inc. (Italy) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 134. Alfasigma USA, Inc. (Italy) Recent Development
Table 135. RedHill Biopharma Ltd. (Israel) Company Details
Table 136. RedHill Biopharma Ltd. (Israel) Business Overview
Table 137. RedHill Biopharma Ltd. (Israel) Product
Table 138. RedHill Biopharma Ltd. (Israel) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 139. RedHill Biopharma Ltd. (Israel) Recent Development
Table 140. AstraZeneca (U.K) Company Details
Table 141. AstraZeneca (U.K) Business Overview
Table 142. AstraZeneca (U.K) Product
Table 143. AstraZeneca (U.K) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 144. AstraZeneca (U.K) Recent Development
Table 145. Ipsen (France) Company Details
Table 146. Ipsen (France) Business Overview
Table 147. Ipsen (France) Product
Table 148. Ipsen (France) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 149. Ipsen (France) Recent Development
Table 150. Novartis AG (Switzerland) Company Details
Table 151. Novartis AG (Switzerland) Business Overview
Table 152. Novartis AG (Switzerland) Product
Table 153. Novartis AG (Switzerland) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 154. Novartis AG (Switzerland) Recent Development
Table 155. Takeda Pharmaceutical Company Ltd (Japan) Company Details
Table 156. Takeda Pharmaceutical Company Ltd (Japan) Business Overview
Table 157. Takeda Pharmaceutical Company Ltd (Japan) Product
Table 158. Takeda Pharmaceutical Company Ltd (Japan) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 159. Takeda Pharmaceutical Company Ltd (Japan) Recent Development
Table 160. Synthetic Biologics, Inc. (U.S.) Company Details
Table 161. Synthetic Biologics, Inc. (U.S.) Business Overview
Table 162. Synthetic Biologics, Inc. (U.S.) Product
Table 163. Synthetic Biologics, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 164. Synthetic Biologics, Inc. (U.S.) Recent Development
Table 165. Protagonist Therapeutics Inc. (U.S.) Company Details
Table 166. Protagonist Therapeutics Inc. (U.S.) Business Overview
Table 167. Protagonist Therapeutics Inc. (U.S.) Product
Table 168. Protagonist Therapeutics Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 169. Protagonist Therapeutics Inc. (U.S.) Recent Development
Table 170. Pfizer Inc (U.S.) Company Details
Table 171. Pfizer Inc (U.S.) Business Overview
Table 172. Pfizer Inc (U.S.) Product
Table 173. Pfizer Inc (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 174. Pfizer Inc (U.S.) Recent Development
Table 175. Lexicon Pharmaceuticals, Inc. (U.S.) Company Details
Table 176. Lexicon Pharmaceuticals, Inc. (U.S.) Business Overview
Table 177. Lexicon Pharmaceuticals, Inc. (U.S.) Product
Table 178. Lexicon Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 179. Lexicon Pharmaceuticals, Inc. (U.S.) Recent Development
Table 180. Innovate Biopharmaceuticals (U.S.) Company Details
Table 181. Innovate Biopharmaceuticals (U.S.) Business Overview
Table 182. Innovate Biopharmaceuticals (U.S.) Product
Table 183. Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2015-2020) (Million US$)
Table 184. Innovate Biopharmaceuticals (U.S.) Recent Development
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. Global IBS Treatment Market Share by Type: 2020 VS 2026
Figure 2. IBS-D Features
Figure 3. IBS-C Features
Figure 4. IBS-M Features
Figure 5. Global IBS Treatment Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Research Laboratories Case Studies
Figure 9. IBS Treatment Report Years Considered
Figure 10. Global IBS Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global IBS Treatment Market Share by Regions: 2020 VS 2026
Figure 12. Global IBS Treatment Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global IBS Treatment Market Share by Players in 2019
Figure 15. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in IBS Treatment as of 2019
Figure 16. The Top 10 and 5 Players Market Share by IBS Treatment Revenue in 2019
Figure 17. North America IBS Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe IBS Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China IBS Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan IBS Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia IBS Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India IBS Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America IBS Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
気管支炎治療の世界市場（～2026年） Bronchitis is a respiratory disease in which there is inflammation of the bronchi in the lungs. In other words, bronchitis is an inflammation of the lining of bronchial tubes that carry air to and from the lungs. Some of the common signs and symptoms of bronchitis include cough, fatigue, shortness o…- 胃炎治療の世界市場（～2026年） Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a long duration. There may be no symptoms but, when symptoms are present, the most common is upper abdominal pain. Other possible symptoms include nausea and vomiting, bloating, loss of appetite and …
- ハンセン病治療の世界市場（～2026年） Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacterium Mycobacterium leprae or Mycobacterium lepromatosis. Initially, infections are without symptoms and typically remain this way for 5 to 20 years. Symptoms that develop include granulomas of the nerves, respiratory …
- 線維肉腫治療の世界市場（～2026年） Fibrosarcoma is cancer, which is a part of larger collection of cancers known as sarcomas. Fibrosarcoma is generally treated with the help of chemotherapy. Market Analysis and Insights: Global Fibrosarcoma Treatment Market The global Fibrosarcoma Treatment market size is projected to reach US$ XX mi…
- HIV診断・治療の世界市場（～2026年） HIV prevalence in Africa, specifically in Southern region is very high as compared to North African region. Approximately 1 out of 4 is suffering from HIV. Southern and Eastern region of Africa has one of the highest prevalence rate of HIV, about 19 million people have HIV. While HIV prevalence is l…